Comparing biote (BTMD) & Its Competitors

biote (NASDAQ:BTMD – Get Rating) is one of 58 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its rivals? We will compare biote to similar businesses based on the strength of its institutional ownership, dividends, earnings, risk, valuation, analyst recommendations and profitability.

Profitability

This table compares biote and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
biote	56.20%	-46.62%	29.08%
biote Competitors	-10.38%	-101.91%	21.35%

Insider & Institutional Ownership

3.8% of biote shares are owned by institutional investors. Comparatively, 14.3% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 16.6% of biote shares are owned by company insiders. Comparatively, 21.8% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for biote and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
biote	0	0	5	0	3.00
biote Competitors	214	568	818	46	2.42

biote currently has a consensus price target of $10.40, suggesting a potential upside of 97.34%. As a group, “Medicinals & botanicals” companies have a potential upside of 109.41%. Given biote’s rivals higher probable upside, analysts clearly believe biote has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares biote and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
biote	$164.96 million	-$970,000.00	87.85
biote Competitors	$290.64 million	-$110.28 million	-1.82

biote’s rivals have higher revenue, but lower earnings than biote. biote is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

biote has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, biote’s rivals have a beta of 1.16, suggesting that their average stock price is 16% more volatile than the S&P 500.

Summary

biote beats its rivals on 7 of the 13 factors compared.

About biote

(Get Rating)

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.